Pharmacopsychiatry最新文献_第3页

Using Classification and Regression Tree Modeling to Investigate the Effects of Subanesthetic Ketamine Infusion on Remission of Suicidal Symptoms. 应用分类回归树模型研究亚麻醉氯胺酮输注对自杀症状缓解的影响。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2026-02-26 DOI: 10.1055/a-2807-8161

Ping-Chung Wu, Wei-Chen Lin, Tung-Ping Su, Cheng-Ta Li, Hui-Ju Wu, Shih-Jen Tsai, Ya-Mei Bai, Pei-Chi Tu, Wei-Chung Mao, Mu-Hong Chen

{"title":"Using Classification and Regression Tree Modeling to Investigate the Effects of Subanesthetic Ketamine Infusion on Remission of Suicidal Symptoms.","authors":"Ping-Chung Wu, Wei-Chen Lin, Tung-Ping Su, Cheng-Ta Li, Hui-Ju Wu, Shih-Jen Tsai, Ya-Mei Bai, Pei-Chi Tu, Wei-Chung Mao, Mu-Hong Chen","doi":"10.1055/a-2807-8161","DOIUrl":"https://doi.org/10.1055/a-2807-8161","url":null,"abstract":"As accumulating evidence suggests the antisuicidal properties of ketamine, elucidating its underlying mechanisms and predictors of treatment response has become crucial. Whether a combination of clinical markers can enhance the prediction of the antisuicidal response to ketamine remains unclear.Using data from our previous randomized placebo-controlled and open-label trials, this post hoc analysis evaluated 67 patients with treatment-resistant depression and prominent suicidal ideation who received a single ketamine infusion of 0.5 mg/kg. A classification and regression tree model was used to identify the combinations of clinical and demographic characteristics at baseline that can predict the antisuicidal response to ketamine infusion.Combinations of clinical predictors, including mild or moderate depression severity, a shorter duration of the current episode, no more than four trials of antidepressant failures, low or moderate current suicide risks, and a history of suicide attempts, offered superior predictive power for the rapid and sustained antisuicidal effects of sub-anesthetic ketamine infusion, outperforming the predictive power of any individual predictor.Clinicians can use our findings to identify individuals who are most likely to benefit from the antisuicidal effects of ketamine. Further research is required to corroborate these findings.CART found combined baseline markers, including mild/moderate depression, shorter episode, ≤4 failed antidepressants, low/moderate suicide risk, and prior attempts, predict rapid/sustained antisuicidal response of sub-anesthetic ketamine in TRD.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147308382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antipsychotic Medication Preferences: A Large-Scale Survey. 抗精神病药物偏好：一项大规模调查。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2026-02-19 DOI: 10.1055/a-2784-3444

Babet N Wezenberg, Jara Bouws, Marieke van der Pluijm, Mariken B de Koning, Martijn Kikkert, Matthijs Blankers, Iris E Sommer, Floor A van Dijk, Lieuwe de Haan

{"title":"Antipsychotic Medication Preferences: A Large-Scale Survey.","authors":"Babet N Wezenberg, Jara Bouws, Marieke van der Pluijm, Mariken B de Koning, Martijn Kikkert, Matthijs Blankers, Iris E Sommer, Floor A van Dijk, Lieuwe de Haan","doi":"10.1055/a-2784-3444","DOIUrl":"https://doi.org/10.1055/a-2784-3444","url":null,"abstract":"Antipsychotic medications are essential in treating psychotic disorders; yet, large-scale studies examining individual patient preferences are lacking. The current study explores variations in patient perspectives on antipsychotic treatment.Data were derived from the online decision aid Personal Antipsychotic Choice Index in the Netherlands. This freely available 30-item questionnaire assessed preferred treatment effectiveness, side effects, administration routes, and demographics, psychosis history, and antipsychotic use. Non-parametric tests compared responses by sex, age, and D2-receptor affinity of used medication.Of 23,733 completed questionnaires, 8,743 individuals with at least one psychotic episode were included (mean age: 38.8 and male: 58.8%). Psychotic symptom efficacy was rated most important (75.4%) followed by cognitive (61.9%) and depressive (49.5%) symptom efficacy (both p<0.001). Women rated psychotic and depressive symptom efficacy more important than men (p=0.003 and p<0.001), while adolescents prioritized cognitive symptom efficacy over adults (p=0.004). Extrapyramidal symptoms (73.2%) and weight gain (68.0%) were least acceptable side effects, particularly among women (both p<0.001). Men found sexual dysfunction less tolerable than women (p<0.001). Daily tablets were considered most acceptable (91.0%), followed by weekly tablets (40.1%), injectables (32.7%), and drops (27.9%). Patients using low D2-affinity agents were more willing to accept dizziness (p=0.002) and hypersalivation (p<0.001) than high-affinity users, who in turn accepted sexual dysfunction and menstrual problems more often (both p<0.001).Patient preferences regarding antipsychotic medication vary widely. Incorporating these perspectives through shared decision-making may improve trust and adherence.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Reference Ranges for ADHD Drugs in Blood of Children and Adolescents: A Systematic Review by the AGNP TDM-Task Force. 儿童和青少年血液中ADHD药物的治疗参考范围：AGNP tdm工作组的系统综述。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2026-01-01 Epub Date: 2025-11-03 DOI: 10.1055/a-2689-4911

Sarah S Hagenkötter, Karin Egberts, Stefanie Fekete, Christoph Hiemke, Reinhold Rauh, Hans-Willi Clement, Monica Biscaldi, Christian Fleischhaker, Manfred Gerlach

{"title":"Therapeutic Reference Ranges for ADHD Drugs in Blood of Children and Adolescents: A Systematic Review by the AGNP TDM-Task Force.","authors":"Sarah S Hagenkötter, Karin Egberts, Stefanie Fekete, Christoph Hiemke, Reinhold Rauh, Hans-Willi Clement, Monica Biscaldi, Christian Fleischhaker, Manfred Gerlach","doi":"10.1055/a-2689-4911","DOIUrl":"10.1055/a-2689-4911","url":null,"abstract":"Attention deficit-/hyperactivity disorder (ADHD) medications are commonly prescribed to children and adolescents, but therapeutic reference ranges have not been systematically evaluated yet. This study aimed to establish preliminary therapeutic reference ranges for methylphenidate (MPH), d-amphetamine (d-AMP), atomoxetine (ATX), and guanfacine (GFC), based on a systematic review of the existing relevant literature.Therapeutic reference ranges were calculated based on blood concentrations measured in responder children and adolescents with ADHD. Therapeutic ranges were determined both as mean values plus one standard deviation (SD) and using the 25th/75th IQRs. For MPH, a therapeutic reference range was calculated according to the mean maximum concentration (Cmax)±SD (8.8±7.7 ng/mL) as 1.1-16.6 ng/mL and according to the 25th/75th IQR as 7.2-11.3 ng/mL. The mean d-AMP Cmax concentration±SD was 31.9±15.2 ng/mL, resulting in a range of 16.6-47.1 ng/mL, and the calculated range according to IQR 25th/75th was 18.4-32.5 ng/mL. For ATX, mean maximum concentration at steady state (Cmax,ss)±SD was 589.7±656.3 ng/mL, resulting in a range of 0.0-1245.9 ng/mL, and according to 25th/75th IQR, the range was calculated as 537.0-635.5 ng/mL. For GFC, only one study was eligible, with a mean blood concentration of 7.5 ng/mL in responders.The results provide preliminary recommendations that can serve as reference values for therapeutic drug monitoring in children and adolescents treated with MPH, AMP, ATX, and GFC. Further research is needed to validate or refine the proposed therapeutic ranges.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"15-34"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of Stress-Induced Cortisol Effects on Decision Making After Pharmacological Mineralocorticoid or Glucocorticoid Receptor Blockade. 药物矿皮质激素或糖皮质激素受体阻断后应激诱导皮质醇对决策影响的研究。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2026-01-01 Epub Date: 2025-07-23 DOI: 10.1055/a-2646-7444

Christian E Deuter, Theresa-Svea Weiß, Linn K Kuehl, Christian Otte, Katja Wingenfeld

{"title":"Investigation of Stress-Induced Cortisol Effects on Decision Making After Pharmacological Mineralocorticoid or Glucocorticoid Receptor Blockade.","authors":"Christian E Deuter, Theresa-Svea Weiß, Linn K Kuehl, Christian Otte, Katja Wingenfeld","doi":"10.1055/a-2646-7444","DOIUrl":"10.1055/a-2646-7444","url":null,"abstract":"Acute stress, potentially mediated by the stress-induced release of cortisol, affects decision-making processes. In the brain, cortisol activates two different types of receptors: the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), each with different functional profiles. While previous studies suggest specific effects for MR and GR, the role of both receptor types in decision-making is insufficiently investigated.In this study, stress-induced effects of cortisol on decision-making processes were investigated after pharmacological receptor blockade of the MR (spironolactone, 300 mg) or the GR (mifepristone, 600 mg) in 318 healthy men (M=25.42, SD=5.01). After single-dose administration, participants were subjected to a social-evaluative stress task (Trier Social Stress Test, TSST), which reliably activates the HPA-axis, or a non-stressful control task (pTSST). Participants were randomly assigned to one study group: pTSST-placebo, TSST-placebo, TSST-spironolactone, or TSST-mifepristone. Subsequently, participants completed the Iowa Gambling Task (IGT) as an outcome measure. A mediation analysis was conducted to investigate direct effects of experimental manipulation in this study and indirect effects mediated by cortisol levels. The evidence for stress effects on decisions under ambiguity was positive.While stressed participants exhibited higher risk-taking, this was not the case in the TSST-spironolactone group, although this group had the most pronounced cortisol stress response. Thus, cortisol did not mediate this effect.The stress effect on decision-making was attenuated when MR was blocked. This corresponds to previous findings of increased risk-taking after MR activation and highlights a functional differentiation of both receptors for this domain.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"44-51"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Lumateperone Effective in Bipolar Depression? A Systematic Literature Review and Meta-Analysis on Placebo-Controlled Trials. Lumateperone对双相抑郁症有效吗？安慰剂对照试验的系统文献综述和荟萃分析。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2026-01-01 Epub Date: 2025-07-14 DOI: 10.1055/a-2579-9406

Maurizio Pompili, Mariarosaria Cifrodelli, Maria Anna Trocchia, Ludovica Longhini, Anna Comparelli, Roger S McIntyre, Isabella Berardelli

{"title":"Is Lumateperone Effective in Bipolar Depression? A Systematic Literature Review and Meta-Analysis on Placebo-Controlled Trials.","authors":"Maurizio Pompili, Mariarosaria Cifrodelli, Maria Anna Trocchia, Ludovica Longhini, Anna Comparelli, Roger S McIntyre, Isabella Berardelli","doi":"10.1055/a-2579-9406","DOIUrl":"10.1055/a-2579-9406","url":null,"abstract":"Bipolar depression is often difficult to treat and needs a specific therapeutic approach. This systematic review and meta-analysis aimed to evaluate the efficacy of lumateperone to be inclusive of more recently published studies with this agent in depressive episodes of bipolar disorder. Three meta-analyses were conducted to determine whether the mean Montgomery-Asberg Depression Rating Scale (MADRS) values in the placebo groups differ significantly from the mean MADRS scale values in the group receiving lumateperone 42 mg and whether the mean of Clinical Global Impression Bipolar Version - Severity Scale (CGI-BP-S) - (depression subscore and overall bipolar illness) values in the placebo groups differ significantly from the mean CGI-BP-S scale values in the group receiving lumateperone 42 mg. The meta-analysis showed a statistically significant difference between patients treated with lumateperone 42 mg and those treated with placebo for the MADRS and CGI subscores. The clinical profile of lumateperone indicates that it is a established and highly efficacious treatment option for major depressive episodes associated with bipolar disorder.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"5-14"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antipsychotic Polypharmacy and Epigenetic Age Acceleration in Schizophrenia. 精神分裂症的抗精神病药物和表观遗传年龄加速。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2026-01-01 Epub Date: 2025-11-03 DOI: 10.1055/a-2668-0722

George Nader, Adrian Yung, Yuyang Liang, Matisse Ducharme, Corinne Fischer, Philip Gerretsen, Ariel Graff, Vincenzo De Luca

{"title":"Antipsychotic Polypharmacy and Epigenetic Age Acceleration in Schizophrenia.","authors":"George Nader, Adrian Yung, Yuyang Liang, Matisse Ducharme, Corinne Fischer, Philip Gerretsen, Ariel Graff, Vincenzo De Luca","doi":"10.1055/a-2668-0722","DOIUrl":"10.1055/a-2668-0722","url":null,"abstract":"Schizophrenia spectrum disorders (SSD) are debilitating psychiatric illnesses that require extensive pharmacologic, cognitive, and functional management. SSD patients are often prescribed different medications, most commonly antipsychotics, which bear numerous side effects. Recently, accumulating evidence has shown epigenetic aging changes in SSD. However, the effects of antipsychotic medications on this phenomenon remain unexplored.We investigated whether antipsychotic medications are associated with epigenetic age acceleration (EAA) in 153 SSD patients. EAA was estimated using six different epigenetic clocks, based on the methylation patterns of peripheral blood cells.The analysis revealed some evidence of aging deceleration based on the Hannum DNAm Age in individuals on antipsychotic polypharmacy, relative to their monopharmacy counterparts (mean difference=-0.59 years, p=0.0109), which was only nearing significance after adjusting for multiple comparisons (padjusted=0.0654). In sex-specific analysis, only females displayed significantly decelerated epigenetic aging in the polypharmacy group in three of the six clocks. Furthermore, we observed no dose-dependent effects of antipsychotics on EAA in all clocks using three dose standardization methods (daily defined dose, chlorpromazine equivalents, and percent of maximum allowed dose).The findings suggest that antipsychotic treatment may modulate biological aging in SSD; however, this effect is not dose-dependent. Moreover, there appears to be an interplay between sex, polypharmacy, and epigenetic aging. These findings contribute to our understanding of the biological effects of antipsychotic treatment, and future research in this area is key for weighing the benefits and the risks of pharmacological management of SSD.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"35-43"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses. 非选择性单胺氧化酶抑制剂和鼻内艾氯胺酮联合治疗抑郁症对心血管的影响——贝叶斯分析的准实验设计。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2025-11-01 Epub Date: 2025-06-02 DOI: 10.1055/a-2590-3469

Ludovic C Dormegny-Jeanjean, Suzie Lenoir, Ilia Humbert, Olivier A E Mainberger, Coraline Lozere, Camille Meyer, Bernard Geny, Bruno Michel, Jack R Foucher, Clément de Crespin de Billy

{"title":"Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses.","authors":"Ludovic C Dormegny-Jeanjean, Suzie Lenoir, Ilia Humbert, Olivier A E Mainberger, Coraline Lozere, Camille Meyer, Bernard Geny, Bruno Michel, Jack R Foucher, Clément de Crespin de Billy","doi":"10.1055/a-2590-3469","DOIUrl":"10.1055/a-2590-3469","url":null,"abstract":"Ketamine and esketamine (ESK) offer new treatment options for resistant depression. Unlike traditional antidepressants, they can be used in combination with non-selective monoamine oxidase inhibitors (NS-MAOI) without the risk of serotonergic syndrome. However, potential sympathomimetic synergy may lead to elevated blood pressure (BP). This series investigates whether cardiovascular parameters (heart rate, systolic [SP], and diastolic [DP] pressures) increase during ESK sessions and whether the ESK+NS-MAOI combination is associated with BP elevations.We collected cardiovascular parameters for ESK sessions conducted between 2018 and 2022. These parameters were measured at baseline and every 30 min for 2 h. Patients were categorized into two non-equivalent groups: those receiving ESK alone and those receiving ESK+NS-MAOI. A Bayesian random model was used to estimate the evolution of these parameters, while a Bayesian hierarchical model assessed factors contributing to BP elevation.ESK sessions (n=193), of which 116 involved NS-MAOI, were performed in 13 patients. SP, DP, and heart rate showed peak increases during sessions, but these changes were not clinically significant (SP+8.68 mmHg, DP+6.57 mmHg, and heart rate+3.5 bpm). No significant differences were found between the ESK-alone and ESK+NS-MAOI groups. The combination was not identified as a factor linked to BP elevations.These findings align with previous research on ketamine derivatives and suggest minimal peripheric sympathomimetic synergy with NS-MAOI. Bayesian models were used to account for biases intrinsically related to these ecological data and provide a foundation for future open adversarial collaborations. Registration NCT05530668.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"273-283"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time-Dependent Effects of Metformin and Olanzapine on the Metabolic System. 二甲双胍和奥氮平对代谢系统的时间依赖性影响。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2025-11-01 Epub Date: 2025-07-10 DOI: 10.1055/a-2634-7726

Gizem Kurt, Seyda T Durhan, Mehmet Ak, Tulin Yanik

{"title":"Time-Dependent Effects of Metformin and Olanzapine on the Metabolic System.","authors":"Gizem Kurt, Seyda T Durhan, Mehmet Ak, Tulin Yanik","doi":"10.1055/a-2634-7726","DOIUrl":"10.1055/a-2634-7726","url":null,"abstract":"Second-generation antipsychotic drugs, such as olanzapine, have been associated with metabolic side effects including significant weight gain. Recent evidence suggests that this adverse effect may be attenuated by metformin.Male Wistar rats were chronically treated with olanzapine, together with or without metformin, for 7 and 14 weeks. Feeding behavior, food intake, and weight gain were recorded, as well as plasma leptin and triglyceride levels were measured. The expression of hypothalamic candidate genes, Pomc and Npy, involved in appetite and energy balance expressions' was assessed by quantitative real-time polymerase chain reaction.Olanzapine alone caused significant body weight gain, and the co-administration of metformin for 14 weeks lowered body weight and food intake compared with both the 7-week and control groups. Plasma triglyceride levels did not differ among groups. Leptin levels were significantly higher in the olanzapine-only group and were lower in both metformin-olanzapine groups, more promising in the early co-treatment with metformin. Compared to the control group, the hypothalamus of the olanzapine treatment group exhibited downregulated Pomc expression and upregulated Npy expression.Early co-treatment with metformin significantly mitigated olanzapine-induced weight gain and food intake, demonstrating its potential in preventing metabolic side effects when initiated at the beginning of antipsychotic therapy.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"285-292"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder. 新型GLP-1受体激动剂Semaglutide治疗酒精使用障碍的潜力

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2025-11-01 Epub Date: 2025-04-14 DOI: 10.1055/a-2550-6470

Tingting Liu, Fuqiang Shi, Zhihua Guo, Hongwu Li, Di Qin

{"title":"Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.","authors":"Tingting Liu, Fuqiang Shi, Zhihua Guo, Hongwu Li, Di Qin","doi":"10.1055/a-2550-6470","DOIUrl":"10.1055/a-2550-6470","url":null,"abstract":"Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious health and social consequences. However, few licensed and successful pharmacotherapies exist for heterogeneous and complex disorders such as AUD, and these are poorly utilized. Preclinical and clinical findings suggest that the glucagon-like peptide-1 (GLP-1) system, a gut-brain peptide, is involved in the neurobiology of addictive behaviors. Additionally, the GLP-1 receptor (GLP-1R) has become a promising target for the treatment of AUD. Semaglutide, a novel GLP-1R agonist, has received clinical approval to treat type 2 diabetes in both subcutaneous and oral dosage forms. Studies have shown that it significantly reduces alcohol consumption and relapse of alcohol addiction in rats, suggesting its potential effectiveness for treating alcohol abuse in humans, particularly in overweight patients with AUDs. However, the use of semaglutide is associated with potential risks, such as gallbladder disease and clinical complications associated with delayed gastric emptying. This review evaluates the safety of semaglutide to inform its wider clinical application. Further extensive and in-depth studies on semaglutide are needed to reveal additional valuable clinical benefits.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"255-262"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes. Xanomeline-Trospium用于成人精神分裂症急性精神病患者：安全性和耐受性结果的系统回顾和荟萃分析。

IF 2.2 3区医学

Pharmacopsychiatry Pub Date : 2025-11-01 Epub Date: 2025-01-29 DOI: 10.1055/a-2506-7022

Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Masakazu Hatano, Osamu Furukawa, Youichi Saito, Nakao Iwata

{"title":"Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes.","authors":"Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Masakazu Hatano, Osamu Furukawa, Youichi Saito, Nakao Iwata","doi":"10.1055/a-2506-7022","DOIUrl":"10.1055/a-2506-7022","url":null,"abstract":"The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson-Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo. Notably, xanomeline-trospium demonstrated superior efficacy than placebo in improving the Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive subscale score, and PANSS negative subscale score.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"249-254"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0